Immunoadsorption in steroid-refractory multiple sclerosis

Atherosclerosis Supplements

Volumn 14, Issue 1, 2013, Pages 175-178

  Koziolek, Michael J ^a   Kitze, Bernd ^a   Mühlhausen, Johannes ^a   Müller, Gerhard A ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Apheresis; ASFA; EDSS; IA; Immunoadsorption; MBP; MOG; MS; Multiple sclerosis; Neuroinflammation; PE; Plasma exchange; VEPs

Indexed keywords

CORTICOSTEROID;

ARTICLE; EXTENDED DISABILITY STATUS SCALE; HISTOPATHOLOGY; HUMAN; IMMUNOADSORPTION; MULTIPLE SCLEROSIS; OPTIC NEURITIS; PATIENT SAFETY; PLASMAPHERESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RATING SCALE; RETROSPECTIVE STUDY; STEROID REFRACTORY MULTIPLE SCLEROSIS; THERAPY EFFECT;

ABSORPTION; AUTOANTIBODIES; AUTOIMMUNITY; BIOLOGICAL MARKERS; BLOOD COMPONENT REMOVAL; DISABILITY EVALUATION; DRUG RESISTANCE; HUMANS; IMMUNOSORBENT TECHNIQUES; IMMUNOSORBENTS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PLASMA EXCHANGE; RECOVERY OF FUNCTION; STEROIDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84872859037     PISSN: 15675688     EISSN: 18785050     Source Type: Journal    
DOI: 10.1016/j.atherosclerosissup.2012.10.026     Document Type: Article

References (25)

1. Szczepiorkowski Z.M., Winters J.L., Bandarenko N., Kim H.C., Linenberger M.L., Marques M.B., et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the apheresis applications: Committee of the American Society for Apheresis. J Clin Apher 2010, 25:83-177.
2. Keegan M., Konig F., McClelland R., Bruck W., Morales Y., Bitsch A., et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 2005, 366(9485):579-582.
3. Wilson H.L. B cells contribute to MS pathogenesis through antibody-dependent and antibody-independent mechanisms. Biologics 2012, 6:117-123.
4. Meuth S.G., Göbel K., Wiendl H. Immune therapy of multiple sclerosis - future strategies. Curr Pharm Des 2012, [Epub ahead of print].
5. Wiendl H., Toyka K.V., Rieckmann P., Gold R., Hartung H.P., Hohlfeld R. Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol 2008, 255:1449-1463. Multiple Sclerosis Therapy Consensus Group (MSTCG).
6. Reindl M., Linington C., Brehm U., Egg R., Dilitz E., Heisenhammer F., et al. Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological disease: a comparative study. Brain 1999, 122:2047-2056.
7. Berger T. Is there a rationale for therapeutic immunoadsorption in multiple sclerosis?. Eur J Clin Invest 2005, 35(8):467-468.
8. Kuerten S., Pauly R., Blaschke S., Rottlaender A., Kaiser C.C., Schroeter M., et al. Fortschr Neurol Psychiatr 2011, 79(2):83-91.
9. Klingel R., Heibges A., Fassbender C. Plasma exchange and immunoadsorption for autoimmune neurologic diseases - current guidelines and future perspectives. Atheroscler Suppl 2009, 10(5):129-132.
10. Weinshenker B.G., O'Brien P.C., Petterson T.M., Noseworthy J.H., Lucchinetti C.F., Dodick D.W., et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999, 46(6):878-886.
11. Linker R.A., Chan A., Sommer M., Koziolek M., Muller G.A., Paulus W., Gold R. Plasma exchange therapy for steroid-refractory superimposed relapses in secondary progressive multiple sclerosis. J Neurol 2007, 254(9):1288-1289.
12. Schilling S., Linker R.A., Konig F.B., Koziolek M., Bahr M., Muller G.A., et al. Nervenarzt 2006, 77(4):430-438.
13. Cortese I., Chaudhry V., So Y.T., Cantor F., Cornblath D.R., Rae-Grant A. Evidence-based guideline update: plasmapheresis in neurologic disorders. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2011, 76:294-300.
14. Schröder A., Linker R.A., Gold R. Plasmapheresis for neurological disorders. Expert Rev Neurother 2009, 9(9):1331-1339.
15. Bramlage C., Schröder C., Bramlage P., Ahrens K., Zapf A., Müller G.A., Koziolek M.J. Predictors of complications of therapeutical plasma exchange. J Clin Apher 2009, 24(6):225-231.
16. Köhler W., Bucka C., Klingel R. A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis. J Clin Apher 2011, 26(6):347-355.
17. Belàk M., Borberg H., Jimenez C., Oette K. Technical and clinical experience with protein A immunoadsorption columns. Transfus Sci 1994, 15(4):419-422.
18. Yeh J.H., Chiu H.C. Comparison between double-filtration plasmapheresis and immunoadsorption plasmapheresis in the treatment of patients with myasthenia gravis. J Neurol 2000, 247(7):510-513.
19. Charlton B., Antony G., Cooper S.G., Schindhelm K. A comparison of the effects of plasma exchange and immunoadsorption on anti-insulin antibody synthesis in rabbits. Clin Exp Immunol 1988, 72(2):326-329.
20. Koziolek M.J., Tampe D., Bähr M., Dihazi H., Jung K., Fitzner D., et al. Immunoadsorption therapy in MS patients with steroid-refractory optical neuritis. J Neuroinflammation 2012, [Epub ahead of print].
21. Hosokawa S., Oyamaguchi A., Yoshida O. Successful immunoadsorption with membrane plasmapheresis for multiple sclerosis. ASAIO Trans 1989, 35(3):576-577.
22. de Andrés C., Anaya F., Giménez-Roldán S. Plasma immunoadsorption treatment of malignant multiple sclerosis with severe and prolonged relapses. Rev Neurol 2000, 30(7):601-605.
23. Moldenhauer A., Haas J., Wäscher C., Derfuss T., Hoffmann K.T., Kiesewetter H., Salama A. Immunoadsorption patients with multiple sclerosis: an open-label pilot study. Eur J Clin Invest 2005, 35(8):523-530.
24. Trebst C., Bronzlik P., Kielstein J.T., Schmidt B.M.W., Stangel M. Immunoadsorption therapy for steroid-unresponsive relapses in patients with multiple sclerosis. Blood Purif 2012, 33:1-6.
25. Mauch E., Zwanzger J., Hettich R., Fassbender C., Klingel R., Heigl F. Immunadsorption bei steroidrefraktärem Schub der Multiplen Sklerose. Nervenarzt 2011, 82(12):1590-1595.